Evidence map›Paper›PMID 23122286›Full record

ArticleCell stem cell2012

Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal.

Jin Zhang, Esther Nuebel, George Q Daley, Carla M Koehler, Michael A Teitell

Abstract read
In one paragraph

Article in Cell stem cell, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 286 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
286citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

286 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. The authors respond to feedback onFrontiers in oncology · 2026
    Article
  19. Article
  20. Article

226 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jin ZhangDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Esther Nuebel
George Q Daley
Carla M Koehler
Michael A Teitell

Funding

Customized stem cells for clinical application in blood disordersR24DK092760 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI COLLINS, JAMES J, DALEY, GEORGE Q · 2011 to 2018
$10.7M
Human Embryonic Stem Cell CoreP01GM081621 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZACK, JEROME A. · 2008 to 2012
$9.3M
Human Pluripotent Stem Cell and Progenitor Models of Cardiac and Blood DiseasesU01HL100001 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI DALEY, GEORGE Q, ORKIN, STUART H · 2009 to 2015
$8.9M
Biogenesis of the mitochondrial inner membrane diversity supplementR01GM061721 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KOEHLER, CARLA M · 2000 to 2025
$8.1M
RNA trafficking in mitochondriaR01GM073981 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Carla M Koehler, MICHAEL A TEITELL · 2006 to 2026
$5.1M
Novel therapies for Fanconi anemiaRC4DK090913 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI D'ANDREA, ALAN D., DALEY, GEORGE Q · 2010 to 2010
$3.9M
TCL1 ONCOGENE IN B LYMPHOCYTE DEVELOPMENT AND NEOPLASIAR01CA090571 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TEITELL, MICHAEL A · 2002 to 2015
$3.8M
A Fourth Outcome: DNA Damage and the Differentiation of B CellsR01CA156674 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TEITELL, MICHAEL A · 2011 to 2015
$1.5M
NCI NIH HHS CA156674NCI NIH HHS CA90571NCI NIH HHS R01 CA090571NCI NIH HHS R01 CA156674NHLBI NIH HHS U01 HL100001NHLBI NIH HHS UO1-HL100001NIDDK NIH HHS R24 DK092760NIDDK NIH HHS R24DK092760NIDDK NIH HHS RC4 DK090913NIDDK NIH HHS RC4-DK090913NIGMS NIH HHS GM061721NIGMS NIH HHS GM073981NIGMS NIH HHS P01 GM081621NIGMS NIH HHS P01GM081621NIGMS NIH HHS R01 GM061721NIGMS NIH HHS R01 GM073981PHS HHS PNEY018228
6 · The paper itself

Abstract

Small, rapidly dividing pluripotent stem cells (PSCs) have unique energetic and biosynthetic demands compared with typically larger, quiescent differentiated cells. Shifts between glycolysis and oxidative phosphorylation with PSC differentiation or reprogramming to pluripotency are accompanied by changes in cell cycle, biomass, metabolite levels, and redox state. PSC and cancer cell metabolism are overtly similar, with metabolite levels influencing epigenetic/genetic programs. Here, we discuss the emerging roles for metabolism in PSC self-renewal, differentiation, and reprogramming.

Indexed as

Cellular ReprogrammingCell DifferentiationEnergy MetabolismHumansOxidative PhosphorylationPluripotent Stem Cells

Identifiers

PMID23122286
PMCPMC3492890

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.